Agilent Technologies and Incyte Genomics Announce Patent Portfolio Agreement.

Business Editors/High-Tech Writers

PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 5, 2001

Additional Incyte Patents Consolidate Agilent's Intellectual

Property Portfolio for Production of Printed Custom and Catalog DNA 

Microarrays

Agilent Technologies Inc. (NYSE:A) and Incyte Genomics Inc. (Nasdaq:INCY), the leading genomic information company, today announced a comprehensive licensing agreement that gives Agilent access to Incyte's key microarray and gene expression patents and strengthens Agilent's position as a major manufacturer of printed DNA microarrays.

Included in the agreement are licenses to the nucleic acid linear amplification patents of Eberwine, Van Gelder, Wang and others. Also included are the patent portfolio of Shalon and Brown covering DNA microarrays, their manufacture and use, and the Augenlicht patent covering the use of gene expression arrays in cancer research and diagnosis.

Additionally, Incyte has exclusively licensed Agilent under its comprehensive patent portfolio covering inkjet array manufacture. This portfolio includes the inventions of Gamble, Theriault, Baldeschwieler and Winder for in situ synthesis of nucleic acid microarrays and adds to the considerable inkjet patent portfolio of Agilent, which also includes licenses to Hewlett-Packard Company and Canon inkjet intellectual property.

The exclusive license of Incyte's inkjet patent portfolio and the license to the Shalon/Brown patents will allow Agilent greater flexibility in the design of instruments for the manufacture of printed microarrays. The license to Incyte's gene expression intellectual property, combined with Agilent's own sample preparation technologies, will allow Agilent to provide its customers with the freedom to use "the gold standard" amplification methodologies for their various application needs. Further financial details of the license agreement were not disclosed.

"We are pleased to add the Incyte patents to the already extensive portfolio of Agilent patents and patent licenses," said Barney Saunders, vice president and general manager of Agilent's Bio-Research Solutions. "These patents will consolidate and strengthen Agilent's position as a major manufacturer of printed DNA microarrays and as a supplier of reagents and kits for sample preparation."

"These technology licensing agreements underscore the growing collaborative relationship between Incyte and Agilent, which includes our earlier agreement regarding the supply of cDNA clones and Lifeseq data for Agilent-manufactured arrays," said Roy A. Whitfield, chief executive of Incyte. "Incyte is pleased that Agilent's customers will now have the benefit of Incyte's array technologies as well as Incyte's content."

About Incyte Genomics, Inc.

Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, and related reagents. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at http://www.incyte.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is a global technology leader in communications, electronics and life sciences. The company's 43,000 employees serve customers in more than 120 countries. Agilent had net revenue of $9.4 billion in fiscal year 2000, as restated to reflect the sale of its healthcare business. Information about Agilent is available on the Web at www.agilent.com.

Incyte's Safe Harbor Statement

Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the impact that access to Incyte's microarray and gene expression patents will have on Agilent's competitive position and product design flexibility, the benefit that Agilent's customers will receive as a result of Incyte's array technologies and content, the ability of Incyte's products and services to enhance the research efforts of its customers and Incyte's ability to leverage its intellectual property position to become a leader in therapeutic discoveries, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the ability of the parties to meet the goals of their collaborative relationship; Incyte's ability to enforce drug target patents and changes in laws as they affect such patents; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; changes to Incyte's business plan; alternative technological advances and competition; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements.

Agilent's Safe Harbor Statement

This news release contains forward-looking statements (including, without limitation, statements relating to Agilent's future marketplace position in the design and manufacture of printed microarrays, Agilent's ability to provide optimal amplification methodologies for its customers' various application needs, and the benefit Agilent's customers will receive as a result of Incyte's array technologies and content) that involve risks and uncertainties that could cause results of Agilent Technologies to differ materially from management's current expectations. These risks are detailed in Agilent's Annual Report on Form 10-K for the year ended Oct. 31, 2000, Quarterly Report on Form 10-Q for the quarter ended July 31, 2001, and Current Reports on Form 8-K filed Aug. 15, 2001 and Aug. 22, 2001.

NOTE TO EDITORS: Press releases, photography and other information can be accessed and downloaded from the Agilent Technologies Life Sciences and Chemical Analysis newsrooms at www.agilent.com/about/newsroom/lifesciences/ and www.agilent.com/about/newsroom/chemical/.